Literature DB >> 2365959

High turnover osteoporosis in acro-osteolysis (Hajdu-Cheney syndrome).

V Nunziata1, G di Giovanni, P Ballanti, E Bonucci.   

Abstract

Acro-osteolysis with diffuse osteoporosis in the absence of other associated diseases is named Hajdu-Cheney syndrome. Reduced bone formation rather than enhanced bone resorption has been indicated as the mechanism of osteoporosis. On the assumption that in this syndrome the active bone resorption which produces distal osteolysis must also predominate in generalized osteoporosis, we investigated bone histology, calcium kinetics, calciotropic hormones and bone markers in a patient suffering from sporadic Hajdu-Cheney syndrome. A radius bone biopsy taken far from the osteolytic lesions showed severe osteoporosis with a marked increase in osteoclastic bone resorption and reduced bone formation. Total body calcium clearance, performed through an analysis of the kinetics of calcium infusion, was 2.8 times higher than in normal controls, indicating the presence of active osteoclastic bone resorption. Serum parathormone, 1,25-dihydroxycholecalciferol, alkaline phosphatase and urinary hydroxiproline were in the normal range. These data indicate that in Hajdu-Cheney syndrome trabecular osteoporosis is produced by the same mechanism that induces distal osteolysis, which suggests that it may be sustained by local acting factors stimulating osteoclastic resorption.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365959     DOI: 10.1007/BF03349553

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  20 in total

1.  A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors:  J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

2.  The acro-osteolysis syndrome: Morphologic and biochemical studies.

Authors:  D M Brown; D S Bradford; R J Gorlin; R J Desnick; L O Langer; J Jowsey; J J Sauk
Journal:  J Pediatr       Date:  1976-04       Impact factor: 4.406

3.  Cranio-skeletal dysplasia.

Authors:  N HAJDU; R KAUNTZE
Journal:  Br J Radiol       Date:  1948-01       Impact factor: 3.039

Review 4.  Collagenases (first of three parts).

Authors:  E D Harris; S M Krane
Journal:  N Engl J Med       Date:  1974-09-12       Impact factor: 91.245

5.  A simplified procedure for the measurement of total hydroxyproline in urine.

Authors:  J Cleary; R A Saunders
Journal:  Clin Chim Acta       Date:  1974-12-17       Impact factor: 3.786

6.  Idiopathic nonfamilial acro-osteolysis with cortical defects and mandibular ramus osteolysis.

Authors:  L A Gilula; J Bliznak; T W Staple
Journal:  Radiology       Date:  1976-10       Impact factor: 11.105

7.  The Hajdu-Cheney syndrome. Report of two cases and review of the literature.

Authors:  R G Weleber; R K Beals
Journal:  J Pediatr       Date:  1976-02       Impact factor: 4.406

8.  Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia.

Authors:  S R Nussbaum; R J Zahradnik; J R Lavigne; G L Brennan; K Nozawa-Ung; L Y Kim; H T Keutmann; C A Wang; J T Potts; G V Segre
Journal:  Clin Chem       Date:  1987-08       Impact factor: 8.327

9.  Complement-dependent stimulation of prostaglandin synthesis and bone resorption.

Authors:  L G Raisz; A L Sandberg; J M Goodson; H A Simmons; S E Mergenhagen
Journal:  Science       Date:  1974-08-30       Impact factor: 47.728

10.  Hereditary osteodysplasia with acro-osteolysis. (The Hajdu-Cheney syndrome).

Authors:  A N Elias; R S Pinals; H C Anderson; L V Gould; D H Streeten
Journal:  Am J Med       Date:  1978-10       Impact factor: 4.965

View more
  15 in total

Review 1.  Hajdu-Cheney Syndrome, a Disease Associated with NOTCH2 Mutations.

Authors:  Ernesto Canalis; Stefano Zanotti
Journal:  Curr Osteoporos Rep       Date:  2016-08       Impact factor: 5.096

Review 2.  Notch Signaling and the Skeleton.

Authors:  Stefano Zanotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2016-04-13       Impact factor: 19.871

Review 3.  Clinical and experimental aspects of notch receptor signaling: Hajdu-Cheney syndrome and related disorders.

Authors:  Ernesto Canalis
Journal:  Metabolism       Date:  2017-08-24       Impact factor: 8.694

4.  Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab.

Authors:  Giovanni Adami; Maurizio Rossini; Davide Gatti; Giovanni Orsolini; Luca Idolazzi; Ombretta Viapiana; Aldo Scarpa; Ernesto Canalis
Journal:  Bone       Date:  2016-08-31       Impact factor: 4.398

5.  Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome.

Authors:  Sophia Sakka; Rachel I Gafni; Justin H Davies; Bart Clarke; Peter Tebben; Mark Samuels; Vrinda Saraff; Klaus Klaushofer; Nadja Fratzl-Zelman; Paul Roschger; Frank Rauch; Wolfgang Högler
Journal:  J Clin Endocrinol Metab       Date:  2017-11-01       Impact factor: 5.958

6.  Integrated anti-remodeling and anabolic therapy for the osteoporosis of Hajdu-Cheney syndrome.

Authors:  F E McKiernan
Journal:  Osteoporos Int       Date:  2006-11-14       Impact factor: 4.507

7.  Mutations in NOTCH2 in patients with Hajdu-Cheney syndrome.

Authors:  W Zhao; E Petit; R I Gafni; M T Collins; P G Robey; M Seton; K K Miller; M Mannstadt
Journal:  Osteoporos Int       Date:  2013-02-07       Impact factor: 4.507

Review 8.  Notch signaling in skeletal health and disease.

Authors:  Stefano Zanotti; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2013-05-08       Impact factor: 6.664

9.  Hajdu Cheney Syndrome.

Authors:  Shini Susan Samuel; Shrinath Shetty; Gautham Arunachal; Santosh Koshy; Thomas Vizhalil Paul
Journal:  J Clin Diagn Res       Date:  2016-02-01

10.  Effect of zoledronic acid on acro-osteolysis and osteoporosis in a patient with Hajdu-Cheney syndrome.

Authors:  Sena Hwang; Dong Yoeb Shin; Seong Hwan Moon; Eun Jig Lee; Sung-Kil Lim; Ok Hwa Kim; Yumie Rhee
Journal:  Yonsei Med J       Date:  2011-05       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.